Antibe Therapeutics To Raise $35.1 Million In Bought Deal

Money continues to be raised at a feverish pace in the capital markets, with Antibe Therapeutics (TSX: ATE) the latest firm to announce a significant bought deal financing. The company last night announced that it has entered into an arrangement with Canaccord Genuity to raise $35.1 million in a bought deal financing.

A total of 5.9 million units of the company are to be sold under the offering, with each unit priced at $6.00 each. Each unit contains one common share and one half of a common share purchase warrant, with each warrant containing an exercise price of $7.50 per share and an expiry three years from the date of issuance.

An over-allotment option has also been granted.

Net proceeds from the financing are to be used to fully fund phase three efficacy trials and the remaining non-clinical studies for its lead drug, as well as to complete IND-enabling studies for two products in its pipeline, as well as to advance new drug candidates. Finally, funds will also be used for working capital and general corporate purposes.

The financing is currently slated to close on February 24.

Antibe Therapeutics last traded at $7.00 on the TSX.


Information for this briefing was found via Sedar and Antibe Therapeutics. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

2026 Could Be Gold’s Biggest Year Yet!? | Ryan King – Equinox Gold

Gold Is Screaming Higher While Currencies Burn | Simon Ridgway – Rackla Metals

We Have the Highest-Grade Antimony Deposit in North America!? | Jim Atkinson -Antimony Resources

Recommended

Canadian Copper Secures $8 Million Lead Order From Ocean Partners As Part Of Larger Funding Round

Northern Superior Expands Philibert With 350 Metre Step Out Testing 1.10 g/t Gold Over 25.5 Metres

Related News

Antibe Therapeutics Posts Positive Study Results, Insiders Unload Positions

Antibe Therapeutics (TSXV: ATE) this past week published results on its latest drug development for...

Sunday, June 7, 2020, 01:27:37 PM

Antibe Therapeutics Pauses Otenaproxesul Trial After Exceeding Safety Threshold

Antibe Therapeutics Inc. (TSX: ATE) shared today that it is putting on pause the absorption,...

Tuesday, August 3, 2021, 09:50:31 AM

Antibe: Canaccord Cuts Price Target From $5.00 To $1.20 After Drug Pivot

In early August, Antibe Therapeutics Inc. (TSX: ATE) announced that they have paused their study...

Monday, October 18, 2021, 11:31:00 AM

Antibe: Canaccord Raises Price Target After Q4 Results

On June 28th, Antibe Therapeutics (TSX: ATE) reported their fourth quarter and year-end financials. The...

Friday, July 2, 2021, 12:18:00 PM

Canaccord Drops Antibe’s Price Target To $0.70 Following Asset Sale

Antibe Therapeutics Inc. (TSX: ATE) recently reported their full-year 2022 results, wherein the company reported...

Friday, July 15, 2022, 02:25:00 PM